Jerah Ahmed Ali, Farasani Abdullah, Abu-Tawil Hisham, Kuriri Hadi, Taha Manal Mohamed Elhassan, Abdelwahab Siddig Ibrahim, Albasheer Osama
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.
Biomedical Research Unit, Medical Research Center, Jazan University, Jazan, Saudi Arabia.
J Med Life. 2024 Sep;17(9):886-891. doi: 10.25122/jml-2024-0166.
Coagulation dysfunction has emerged as a significant aspect of COVID-19 pathophysiology, with abnormal coagulation parameters observed in severe cases. This study aimed to investigate the predictive value of coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (PTT), and international normalized ratio (INR) for mortality in patients with COVID-19. A retrospective analysis was conducted on a cohort of patients diagnosed with COVID-19. Coagulation parameters, including PT, PTT, and INR, were measured upon admission. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive performance of these parameters. Sensitivity and specificity were calculated, and the area under the curve (AUC) values were determined. The analysis included 156 patients diagnosed with COVID-19. The -test revealed a significant difference ( < 0.05) in PTT, PT, and INR. PTT demonstrated the highest predictive performance, with an AUC value of 0.68, indicating superior discrimination compared with PT and INR. PTT exhibited a sensitivity of 83% and a specificity of 46% for identifying deceased patients. These findings suggest that PTT may serve as a valuable prognostic marker of mortality risk in patients with COVID-19. Coagulation indicators, particularly PTT, predicted COVID-19 mortality. Monitoring coagulation markers may help stratify the risk and guide treatment. Further research and validation studies are needed to corroborate these findings and to establish the clinical importance of coagulation markers in COVID-19 therapy. COVID-19 coagulation dysfunction mechanisms must be understood in order to design targeted therapies to reduce thrombotic consequences.
凝血功能障碍已成为新型冠状病毒肺炎（COVID-19）病理生理学的一个重要方面，在重症病例中观察到凝血参数异常。本研究旨在探讨凝血参数，包括凝血酶原时间（PT）、活化部分凝血活酶时间（PTT）和国际标准化比值（INR）对COVID-19患者死亡率的预测价值。对一组确诊为COVID-19的患者进行了回顾性分析。入院时测量包括PT、PTT和INR在内的凝血参数。进行受试者工作特征（ROC）曲线分析以评估这些参数的预测性能。计算敏感性和特异性，并确定曲线下面积（AUC）值。分析纳入了156例确诊为COVID-19的患者。t检验显示PTT、PT和INR存在显著差异（P<0.05）。PTT表现出最高的预测性能，AUC值为0.68，表明与PT和INR相比具有更好的区分能力。PTT在识别死亡患者方面的敏感性为83%，特异性为46%。这些发现表明，PTT可能是COVID-19患者死亡风险的一个有价值的预后标志物。凝血指标，特别是PTT，可预测COVID-19患者的死亡率。监测凝血标志物可能有助于分层风险并指导治疗。需要进一步的研究和验证研究来证实这些发现，并确定凝血标志物在COVID-19治疗中的临床重要性。为了设计针对性治疗以减少血栓形成后果，必须了解COVID-19凝血功能障碍的机制。
